LOGIN
WCO-IOF: Changes with QCT, DXA, and TBS between denosumab, alendronate, & placebo
April 2014
WCO-IOF: Changes with QCT, DXA, and TBS between denosumab, alendronate, & placebo
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
Changes in lumbar spine QCT, DXA, and TBS following treatment with denosumab (DMAB), alendronate (ALN), or placebo (PBO) in postmenopausal women with low bone mass
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
215 postmenopausal women with low spine or total hip bone mineral density (BMD) were randomized to treatment with either denosumab, alendronate, or placebo for a period of 12 months. Quantitative computed tomography (QCT) and densitometry (DXA), in addition to a novel trabecular bone score (TBS) were evaluated to determine if a differences exists between the information provided by these three mea...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.